Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ: ABCL )

3.115 +0.185 (+6.31%)
Streaming Delayed Price Updated: 10:41 AM EST, Jan 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Friday Markets Coverage
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
Exposures COVID-19
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed
Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Stock Sank 21.6% in October
The biotech is now down roughly 56% across 2021's trading. 
Via The Motley Fool
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Stock Jumped 19.4% Last Month
Despite last month's gains, the biotech stock is now down roughly 61% year to date. 
Via The Motley Fool
AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies
AbCellera Biologics Inc (NASDAQ: ABCL) and Everest Medicines Limited have entered into a multi-year collaboration and license agreement to discover... 
Via Benzinga
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Cramer's Advice On Ulta Beauty, Laredo Petroleum And More
On CNBC's "Mad Money Lightning Round," Jim Cramer advised a viewer to buy more Ulta Beauty Inc (NASDAQ: ULTA). He likes the stock very much. Cramer doesn't like... 
Via Benzinga
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
From AbCellera Biologics Inc.
Via Business Wire
A Day Of Huge Market Moves
It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. 
Via Talk Markets
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
From AbCellera Biologics Inc.
Via Business Wire
15 Stocks Moving in Friday's Pre-Market Session
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody
The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in... 
Via Benzinga
Exposures COVID-19 Product Safety
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Stock Jumped 7% on Wednesday
The company's drug-development technology is starting to attract attention. 
Via The Motley Fool
Exposures COVID-19
AbCellera Shares Are Moving Higher On Licensing Pact With Moderna
AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for... 
Via Benzinga
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
From AbCellera
Via Business Wire
A Weak Week
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.